标题: |
骨质疏松症治疗药物合理应用专家共识(2023) |
title: |
Expert consensus on rational use of osteoporosis drugs (2023) |
版本: |
原创版 |
version: |
Original |
分类: |
专家共识 |
classification: |
Experts consensus |
领域: |
治疗 |
field: |
Treatment |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
各级临床医务人员 |
Guide users:
|
Health care workers |
证据分级方法: |
牛津循证医学中心临床证据水平分级和推荐级别(OCEBM) |
Evidence grading
method:
|
Oxford Centre for Evidence-Based Medicine: Levels of Evidence |
制定单位: |
中国药学会医院药学专业委员会 |
Formulating unit: |
Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association |
注册时间: |
2023-09-07 |
Registration time: |
注册编号: |
PREPARE-2023CN679 |
Registration number: |
指南制订的目的: |
为临床合理使用抗骨质疏松症药物提供切实可行的科学指导,保障患者的用药获益与安全。 |
Purpose of the guideline:
|
To offer evidence-based and practical recommendations for the rational utilization of osteoporosis medications in clinical settings, with a focus on ensuring patient safety and optimizing treatment outcomes. |